The Acute Heart Failure Therapeutics Market Size in the 7MM is anticipated to sustain a steady CAGR during the forecast period (2025-2034), estimates DelveInsight

DelveInsight's "Acute Heart Failure Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of Acute Heart Failure, historical and forecasted epidemiology as well as the Acute Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Explore the latest insights into the Acute Heart Failure Treatment Market Size and emerging therapies! Read the full report now @ Acute Heart Failure Market Outlook- https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Heart Failure Market Report
• In May 2026- Colorado Prevention Center initiated an international study, randomized, double-blind, placebo-controlled, event-driven trial of finerenone for the treatment of hospitalized heart failure patients with mildly reduced or preserved ejection fraction.
• In April 2026- Cardior Pharmaceuticals GmbH conducted a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12.
• In March 2026- Implicit Bioscience announced a phase 1b study is to determine safety of intravenous IC14 in patient's acute decompensated heart failure. Exploratory biomarkers, clinical outcomes, and pharmacokinetic/pharmacodynamic measurements will be used to design further study of clinical efficacy of IC14 in the treatment of ADHF.
• In February 2026- Juntendo University conducted a EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
• As per the secondary research, in the US, 4.5 to 4.9/1000 people are admitted for heart failure as a primary diagnosis every year, putting the number of Acute Heart Failure admissions in the United States at 1.5 million yearly, ≈25% of patients with heart failure.
• According to National Heart Failure Audit (NHFA), a 2024 real-world analysis in the UK estimated that the incidence of confirmed index heart failure admissions was found to be 65,679.
• As per a research study, out of 3,132,337 eligible patients, 123,925 had heart failure: a prevalence of 3.96%. Of these, 26,368 had newly diagnosed heart failure: an incidence of 655/100,000 persons at risk. Incidence increased with age and was similar regardless of sex.
• The epidemiology of Acute Heart Failure is expected to change during the forecast period (2025-2034).
• The leading Acute Heart Failure Companies such as Abbott, Orion Corporation, Bristol-Myers Squibb, Colorado Prevention Center, Cardioxyl Pharamaceutical Inc., Novartis Pharmaceuticals, Sanjiu Medical & Pharmaceutical Co., Ltd., Boehringer Ingelheim, Innogene Kalbiotech Pte. Ltd and others.
• Promising Acute Heart Failure Pipeline Therapies such as levosimendan, dobutamine, Serelaxin, Shenfu Zhusheye and others.

Stay ahead in the Acute Heart Failure Drugs Market! Get expert analysis on key players, trends, and clinical advancements @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Heart Failure Overview
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. There are two types of heart failure acute and chronic. Acute heart failure has a sudden onset and symptoms can appear without warning. However, in chronic heart failure, that difficulty is ongoing and long-term. It was observed that majority of patients are affected with Chronic heart failure. Acute heart failure is a kind of syndrome that is defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion.

Acute Heart Failure Epidemiology Segmentation in the 7MM
• Acute Heart Failure Prevalent Population
• Acute Heart Failure Diagnosed Prevalent Population
• Acute Heart Failure Gender-specific diagnosed prevalent cases
• Acute Heart Failure Age-specific diagnosed prevalent cases

Download the report to understand which factors are driving Acute Heart Failure Epidemiology trends @ Acute Heart Failure Prevalence- https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Acute Heart Failure Drugs
• INPEFA (sotagliflozin): Lexicon Pharmaceuticals
INPEFA, a novel agent that inhibits sodium-glucose cotransporter SGLT1 as well as SGLT2, received marketing approval from the US FDA in May 2023 for reducing the risk for cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in patients with heart failure, and also for preventing these same events in patients with type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular disease risk factors.

• FARXIGA (dapagliflozin): AstraZenca
FARXIGA is the first in this particular drug class, sodium-glucose co-transporter 2 (SGLT2) inhibitors, to be approved to treat adults with New York Heart Association's functional class II-IV heart failure with reduced ejection fraction. In 2020, the US FDA approved FARXIGA (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.

Emerging Acute Heart Failure Drugs
• Atibuclimab (IC14): Implicit Bioscience
IC14, a monoclonal antibody developed by Implicit Bioscience, is currently advancing through clinical development for the treatment of Acute Heart Failure. By targeting CD14, a key co-receptor involved in the innate immune response and inflammatory signaling, IC14 aims to modulate the excessive immune activation associated with Acute Heart Failure. This therapeutic strategy offers a novel pathway distinct from traditional heart failure treatments. With early studies demonstrating promising anti-inflammatory effects, IC14 holds potential as a targeted option for patients who do not respond adequately to standard therapies.

• MOUNJARO (tirzepatide): Eli Lily
Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%

To know more about Acute Heart Failure treatment guidelines, visit @ Acute Heart Failure Treatment Market Landscape- https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Heart Failure Treatment Market Landscape
The treatment of Acute Heart Failure is well defined in the guidelines and has been demonstrated to improve life expectancy in affected patients. However, for Acute Heart Failure, diuretics, oxygen, and current vasodilators are widely used but have not been shown to reduce mortality. Pharmacotherapy for Acute Heart Failure includes various class of drugs like, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin-receptor blockers (ARB), beta blockers (beta-adrenergic receptor-blocking agents), Aldosterone antagonists, SGLT2 Inhibitors, diuretics etc. being common treatments.

Acute Heart Failure Market Outlook
The report's outlook on the Acute Heart Failure market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Heart Failure therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Heart Failure drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Heart Failure market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Major Acute Heart Failure Companies
Abbott, Orion Corporation, Bristol-Myers Squibb, Colorado Prevention Center, Cardioxyl Pharamaceutical Inc., Novartis Pharmaceuticals, Sanjiu Medical & Pharmaceutical Co., Ltd., Boehringer Ingelheim, Innogene Kalbiotech Pte. Ltd and others.

Which companies are leading the Acute Heart Failure Therapeutics Market? Uncover the competitive landscape and future outlook. Access the report here- https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Heart Failure Market Research Report
• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period- 2024-2034
• Acute Heart Failure Companies- Abbott, Orion Corporation, Bristol-Myers Squibb, Colorado Prevention Center, Cardioxyl Pharamaceutical Inc., Novartis Pharmaceuticals, Sanjiu Medical & Pharmaceutical Co., Ltd., Boehringer Ingelheim, Innogene Kalbiotech Pte. Ltd and others.
• Acute Heart Failure Therapies- levosimendan, dobutamine, Serelaxin, Shenfu Zhusheye and others.
• Acute Heart Failure Market Dynamics: Acute Heart Failure Market Drivers and Barriers
• Acute Heart Failure Market Access and Reimbursement, Unmet Needs and Future Perspectives

What's driving growth in the Acute Heart Failure Drugs Market? Explore trends, opportunities, and market forecasts. Get insights @ Acute Heart Failure Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Acute Heart failure (AHF)
3. Competitive Intelligence Analysis for Acute Heart failure (AHF)
4. Acute Heart failure (AHF): Market Overview at a Glance
5. Acute Heart failure (AHF): Disease Background and Overview
6. Patient Journey
7. Acute Heart failure (AHF) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Heart failure (AHF) Unmet Needs
10. Key Endpoints of Acute Heart failure (AHF) Treatment
11. Acute Heart failure (AHF) Marketed Products
12. Acute Heart failure (AHF) Emerging Therapies
13. Acute Heart failure (AHF): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute Heart failure (AHF)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.